Indhold på blogs repræsenterer udelukkende de enkelte blogforfatteres holdninger.
Indhold på blogs repræsenterer udelukkende de enkelte blogforfatteres holdninger.
Nærsynede børn, der blev behandlet med en gel af medicinen pirenzepine, udviklede deres nærsynethed langsommere end børn behandlet med en placebo-gel.
Desværre kan behandlingen ikke stoppe udviklingen af nærsynethed i disponerede børn, men i forsøget halveredes hastigheden, hvormed nærsynetheden tiltager næsten.
Daily treatment with a medication called pirenzepine can slow the rate of progressive myopia, or nearsightedness, in children, reports a study in the August issue of the Journal of AAPOS (American Association for Pediatric Ophthalmology and Strabismus).
Led by Dr. R. Michael Stiatkowski of Dean McGee Eye Institute/University of Oklahoma Department of Ophthalmology, the researchers evaluated the effects of pirenzepine in children with myopia. Myopia—sometimes called nearsightedness—is a condition in which focus on near objects is good, but distant objects appear blurry. Caused by a problem with the length of the eyeball or the curvature of the cornea, myopia gets worse over time in many children.
In the study, children with myopia were randomly assigned to treatment with pirenzepine gel or an inactive placebo gel. After a year of treatment, the average increase in myopia was significantly less for children using pirenzepine. The new study presents the final results in 84 patients who continued treatment for a total of two years: 53 with pirenzepine and 31 with placebo.
Although myopia worsened in both groups of children, the rate of progression was slower with pirenzepine. At the end of two years, myopia increased by an average of 0.58 diopters in children using pirenzepine versus 0.99 diopters with placebo. (All children initially had "moderate" myopia, with an average refractive error of about -2.00 diopters.)
Indsend kommentar